Pixium Vision S.A.
PXMVF
Other OTC1.50
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
26.84
3Y
-97.39
77.03
5Y
-96.70
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lloyd Diamond
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 74 rue du Faubourg Saint-Antoine Paris France 75012
- IPO Date
- Jul 16, 2021
- Website
- pixium-vision.com
- Similar Companies
- Business
- Pixium Vision S.A. Pixium Vision SA develops bionic vision systems utilizing retinal implants to restore partial visual perception for patients blinded by outer retinal degeneration, including atrophic dry age-related macular degeneration and retinitis pigmentosa; its primary products comprise the PRIMA system, a miniaturized wireless sub-retinal photovoltaic implant with 378 electrodes powered by infrared light from augmented reality glasses and a mini-camera for form vision enabling pattern, letter, and word recognition, and the IRIS II system, an epiretinal implant with 150 bio-inspired electrodes for improved acuity in retinitis pigmentosa patients. The company, founded in 2011 and headquartered at 74 Rue du Faubourg Saint-Antoine in Paris, France, operates in the bioelectronics and neuromodulation sector targeting patients with severe vision loss across Europe and the United States through clinical collaborations with institutions such as Stanford University, Institut de la Vision in Paris, Moorfields Eye Hospital in London, and UPMC in Pittsburgh. In April 2024, following financial difficulties and court-approved liquidation proceedings, Science Corporation acquired Pixium Vision's assets including intellectual property, the PRIMA retinal implant platform, and three ongoing clinical trials such as the European PRIMAvera pivotal study and U.S. feasibility studies, with Science continuing development and reporting in October 2025 that PRIMA restores functional central vision allowing blind patients to read text and complete crosswords as published in the New England Journal of Medicine.